Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sumatriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 9/20 | 0.85 |
| ▸ | HTR1B known ✓ | P28222 | 8/20 | 0.85 |
| ▸ | HTR1A | P08908 | 10/20 | 0.85 |
| ▸ | HTR2A | P28223 | 4/20 | 0.85 |
| ▸ | HTR2C | P28335 | 3/20 | 0.85 |
| ▸ | HTR7 | P34969 | 2/20 | 0.85 |
| ▸ | HTR5A | P47898 | 2/20 | 0.85 |
| ▸ | HTR2B | P41595 | 2/20 | 0.85 |
| ▸ | HTR1E | P28566 | 1/20 | 0.85 |
| ▸ | HTR1F | P30939 | 1/20 | 0.85 |
| ▸ | HTR3A | P46098 | 1/20 | 0.85 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.85 |
| ▸ | HTR6 | P50406 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sumatriptan SCHEMBL2404748 | 1.00 | HTR1A (0.85) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| Sumatriptan SCHEMBL2405528 | 1.00 | HTR1A (0.85) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| Sumatriptan SCHEMBL1556482 | 1.00 | HTR1A (0.85) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| Sumatriptan SCHEMBL29360288 | 1.00 | HTR1A (0.85) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| Sumatriptan SCHEMBL27887904 | 0.99 | HTR1A (0.84) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| Sumatriptan SCHEMBL4132936 | 0.99 | HTR1A (0.84) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| Sumatriptan SCHEMBL6684827 | 0.99 | HTR1A (0.84) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| Sumatriptan SCHEMBL6688024 | 0.97 | HTR1A (0.80) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| Sumatriptan SCHEMBL4308781 | 0.97 | HTR1A (0.80) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| Sumatriptan SCHEMBL4311406 | 0.97 | HTR1A (0.80) | HTR1AHTR1DHTR1BHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7414 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075410-A | Dry powder composition for intranasal delivery | — | 2026-05-26 | — | — | CN | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20250367121-A1 | DOSAGE FORMS COMPRISING ACTIVE PHARMACEUTICAL INGREDIENTS | AXSOME THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-20250235641-A1 | DEVICE TO DELIVER A PREDETERMINED AMOUNT OF A SUBSTANCE TO A NATURAL ORIFICE OF THE BODY | APTARGROUP INC. (US) | 2025-07-24 | — | — | US | claimed |
| US-20250169715-A1 | USE OF BLINK REFLEX FOR HEADACHE RESPONSE MONITORING AND/OR TREATMENT SELECTION | BLINKTBI INC (US) | 2025-05-29 | — | — | US | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| US-20250090778-A1 | Nasal Administration | OPTINOSE AS (NO) | 2025-03-20 | — | — | US | claimed |
| US-20250017902-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MIGRAINE | DR. REDDY’S LABORATORIES LTD. (IN) | 2025-01-16 | — | — | US | claimed |
| EP-1003483-A1 | TANNIC ACID-POLYMER COMPOSITIONS FOR CONTROLLED RELEASE OF PHARMACEUTICAL AGENTS, PARTICULARLY IN THE ORAL CAVITY | Perio Products Ltd (IL) | 2000-05-31 | — | — | EP | claimed |
| JP-2000505090-A | — | — | 2000-04-25 | — | — | JP | claimed |
| CN-1225018-A | Inclusion complex containing indole selective serotonin agonist | FARMARC NEDERLAND BV (NL) | 1999-08-04 | — | — | CN | claimed |
| WO-1999004764-A1 | TANNIC ACID-POLYMER COMPOSITIONS FOR CONTROLLED RELEASE OF PHARMACEUTICAL AGENTS, PARTICULARLY IN THE ORAL CAVITY | PERIO PRODUCTS LTD. (IL) | 1999-02-04 | — | — | WO | claimed |
| WO-1998002186-A1 | INCLUSION COMPLEX CONTAINING INDOLE SELECTIVE SEROTONIN AGONIST | FARMARC NEDERLAND B.V. (NL) | 1998-01-22 | — | — | WO | claimed |
| EP-0574624-B1 | Pharmaceutical compositions | GLAXO LAB SA (FR) | 1997-09-10 | — | — | EP | claimed |
| US-5468504-A | 3-(2-(dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfon -amide succinate in sodium bicarbonate and monosodium citrate; migraines | LABORATOIRES GLAXO S.A. (FR) | 1995-11-21 | — | — | US | claimed |
| EP-0563094-B1 | PHARMACEUTICAL COMPOSITIONS | GLAXO LAB SA (FR) | 1995-09-13 | — | — | EP | claimed |
| EP-0574624-A1 | Pharmaceutical compositions | LABORATOIRES GLAXO SA (FR) | 1993-12-22 | — | — | EP | claimed |
| WO-1992011003-A1 | PHARMACEUTICAL COMPOSITIONS | LABORATOIRES GLAXO S.A. (FR) | 1992-07-09 | — | — | WO | claimed |